REVEAL 2.0风险评分在澳新肺动脉高压登记队列中的回顾性验证
该研究在澳大利亚与新西兰肺动脉高压登记队列(n=1,011)中外部验证REVEAL 2.0风险评分,该队列为现患与 incident 混合队列。结果显示REVEAL 2.0模型区分度良好(C统计量0.74,仅incident队列0.73),三分类模型可稳健区分12个月和60个月生存率(所有风险类别比较P < .001),但完整八层模型中部分中高危层生存估计有重叠。结论支持REVEAL 2.0用于PAH随访风险评估,简化三分类模型可能更适合临床使用。
要点
- REVEAL 2.0在澳新外部队列中验证,C统计量为0.74。
- 三分类模型可稳健区分12个月和60个月生存率(P < .001)。
- 完整八层模型中部分中危和高危层生存估计存在重叠。
核心结论
- REVEAL 2.0风险评分在PHSANZ登记的大规模外部队列中得到验证,可用于PAH患者随访风险评估。
- 简化三分类模型可能更适合临床使用及未来与其他预后模型比较。
研究设计与样本
- 回顾性外部验证研究,应用REVEAL 2.0风险评分于澳大利亚与新西兰肺动脉高压学会(PHSANZ)登记队列中现患与incident混合的PAH患者(n = 1,011)。
- 采用Kaplan-Meier法估计各REVEAL 2.0风险层及简化三分类(低、中、高危)模型的生存率,并对仅incident队列进行敏感性分析。
主要发现
- REVEAL 2.0模型在PHSANZ外部队列中有效区分风险,完整八层模型和三分类模型的C统计量均为0.74。
- 仅应用于incident病例时,C统计量为0.73。
- 三分类REVEAL 2.0模型显示12个月和60个月生存估计的稳健分离(所有风险类别比较P < .001)。
- 完整八层REVEAL 2.0模型虽可区分低、中、高危患者,但部分中危和高危层内的生存估计存在重叠。
关键数值与推荐
- REVEAL 2.0完整八层模型和三分类模型的C统计量均为0.74。
- 仅incident队列的C统计量为0.73。
- 三分类模型所有风险类别比较的12个月和60个月生存估计P < .001。
临床怎么用
- REVEAL 2.0风险评分可用于PAH患者随访时的风险评估。
- 临床使用和未来与其他预后模型比较时,可优先考虑简化三分类模型。
局限性
- 本研究为回顾性验证,非前瞻性设计。
- 完整八层REVEAL 2.0模型中部分中危和高危层的生存估计存在重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary arterial hypertension (PAH) prognosis has improved with targeted therapies; however, the long-term outlook remains poor. Objective multiparametric risk assessment is recommended to identify patients at risk of early morbidity and mortality, and for optimization of treatment. The US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 risk score is a new model proposed for the follow-up of patients with PAH but has not been externally validated. METHODS: The REVEAL 2.0 risk score was applied to a mixed prevalent and incident cohort of patients with PAH (n = 1,011) from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) Registry. Kaplan-Meier survival was estimated for each REVEAL 2.0 risk score strata and for a simplified three-category (low, intermediate, and high risk) model. Sensitivity analysis was performed on an incident-only cohort. RESULTS: The REVEAL 2.0 model effectively discriminated risk in the large external PHSANZ Registry cohort, with a C statistic of 0.74 (both for full eight-tier and three-category models). When applied to incident cases only, the C statistic was 0.73. The three-category REVEAL 2.0 model demonstrated robust separation of 12- and 60-month survival estimates (all risk category comparisons P < .001). Although the full eight-tier REVEAL 2.0 model separated patients at low, intermediate, and high risk, survival estimates overlapped within some of the intermediate- and high-risk strata. CONCLUSIONS: The REVEAL 2.0 risk score was validated in a large external cohort from the PHSANZ Registry. The REVEAL 2.0 model can be applied for risk assessment of patients with PAH at follow-up. The simplified three-category model may be preferred for clinical use and for future comparison with other prognostic models.
引用
- Anderson JJ, Lau EM, Lavender M, et al. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. Chest. 2019. PMID: 31563497. doi:10.1016/j.chest.2019.08.2203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。